Table 4

Best overall tumor response and time to progression

Phase IbPhase II
1100 mg AMG 820 + 200 mg pembrolizumab1400 mg AMG 820 + 200 mg pembrolizumabTotalpMMR CRCPancreatic cancerNSCLCTotal
PD-1-naïve with PDL-1 <50%PD-1 failure with PDL-1 <50%PD-1 failure with PDL-1 ≥50%
Group 1Group 2Group 3Group 4Group 5
n=8n=7n=15n=41n=31n=4n=19n=6n=101
Responses, n (%)
 irPR2 (5)1 (5)3 (3)
 irSD2 (25)2 (29)4 (27)13 (32)8 (26)2 (50)9 (47)3 (50)35 (35)
 irPD3 (38)5 (71)8 (53)21 (51)12 (39)1 (25)4 (21)2 (33)40 (40)
 Not available*3 (38)3 (20)4 (10)11 (36)1 (25)4 (21)1 (17)21 (21)
 Unable to evaluate1 (2)1 (5)2 (2)
KM time to progression
 n10291338457
 Median (range), months1.7 (0.5–5.6)2.0 (0.6–8.4)2.1 (0.3–4.7)5.4 (2.1–6.6)5.1 (1.2–12.0)7.8 (1.9–13.7)2.1 (0.3–13.7)
  • Best overall tumor response (as reported by the investigators) and time to tumor progression were determined according to irRECIST.

  • *Three patients in the phase Ib part and 21 in the phase II part with scans ‘not available’ came off treatment before the initial planned scan. Most of these patients came off treatment due to disease progression.

  • irPD, immune-related progressive disease; irPR, immune-related partial response; irRECIST, immune-related Response Evaluation Criteria in Solid Tumours; irSD, immune-related stable disease; KM, Kaplan-Meier; NSCLC, non-small cell lung cancer; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; pMMR CRC, mismatch repair-proficient colorectal cancer.